Prior to the advent of synthetic nematocides, natural products such as seaweed were used to control nematode infestations. The nematocidal agent in seaweed is betaine, an amino acid that functions as an osmolyte and methyl donor. However, the molecular mechanisms of betaine toxicity are unknown. We identified the betaine transporter SNF-3 and the betaine receptor ACR-23 in the nematode C. elegans. Mutating snf-3 in a sensitized background caused the worms to be hypercontracted and paralyzed, presumably as a result of excess extracellular betaine. These behavioral defects were suppressed by mutations in acr-23, which encodes a ligand-gated cation channel of the cys-loop family. ACR-23 was activated by betaine and functioned in the mechanosensory neurons to maintain basal levels of locomotion. However, overactivation of the receptor by excess betaine or by the allosteric modulator monepantel resulted in hypercontraction and death of the nematode. Thus, monepantel targets a betaine signaling pathway in nematodes.
a r t I C l e S Humans have long competed with parasitic nematodes for crops, livestock and personal health. Early farmers dealt with nematode infestations by using natural pesticides such as wormwood, tobacco and algae (seaweed), which contain natural phytochemicals that interfere with parasitic nematode development [1] [2] [3] . Seaweed extracts are rich in betaines (δ-aminovaleric betaine, γ-amino-butyric betaine and glycine betaine), and direct application of individual betaines to plants suppresses nematode growth as effectively as algal extract 4 .
Glycine betaine, or simply 'betaine' , is a ubiquitous non-canonical amino acid that acts as an osmolyte or as a methyl donor. In addition to its role in metabolism, betaine may have specific roles in the mammalian nervous system. Betaine has anti-epileptic properties [5] [6] [7] and the transporter BGT-1 is localized to dendritic spines and astrocytes in the mammalian brain 8 .
In nematodes, betaine arrests larval development [2] [3] [4] , but the molecular target of betaine is not known. The targets of synthetic anthelmintics are often ligand-gated ion channels. The imidazothiazoles directly activate acetylcholine-gated ion channels, which stimulates muscle contraction and paralyzes the worm 9, 10 . The macrocyclic lactones open glutamate-gated chloride channels and inhibit pharyngeal pumping [11] [12] [13] . Amino-acetonitrile derivatives (AADs) are a recently discovered class of compounds that target a nematodespecific ion channel known as ACR-23 in C. elegans 14 . ACR-23 belongs to the nicotinic acetylcholine receptor subfamily, but its homolog in parasitic nematodes, MPTL-1, is not gated by acetylcholine or choline 15 . The endogenous ligand and biological function of ACR-23 remain to be characterized.
We studied the role of betaine in the nematode C. elegans and found that ACR-23 is a betaine receptor. First, we characterized the betaine transporter SNF-3 and observed that mutations in this transporter were subviable in a sensitized background lacking phospholipase Cβ. Second, mutations in acr-23 suppressed this lethality, suggesting that excess betaine acts via ACR-23. Finally, ACR-23 was gated by betaine and potentiated by the AAD monepantel. Thus, ancient and modern anthelmintics act on the same target: a betaine-activated ion channel that is only found in nematodes.
RESULTS

An enhancer screen identifies a betaine transporter
We were able to identify the betaine pathway inadvertently while studying phospholipase Cβ function. In C. elegans, mutants lacking the only phospholipase Cβ gene (egl-8) exhibit subtle behavioral defects in locomotion and egg-laying, in contrast with the near lethal phenotype of mutants lacking Gαq, the upstream activator of phospholipase Cβ 16, 17 . This modest loss-of-function phenotype in egl-8 mutants suggests the existence of parallel pathways to inositol signaling that modulate locomotion. To uncover these pathways, we performed an F 2 enhancer screen in an egl-8 mutant background. We screened 1,669 haploid genomes and identified a single mutation that caused a synthetic phenotype in the presence of an egl-8 mutation. Mapping, rescue and sequencing experiments revealed that the enhancer was an allele of the snf-3 gene (sodium neurotransmitter symporter family-3; Supplementary Fig. 1a ). The snf-3 egl-8 double mutants exhibited severe synthetic phenotypes ( Fig. 1a-d) : the strain a r t I C l e S was subviable, uncoordinated and dumpy. The dumpy phenotype was a result of hypercontraction of the muscle, as it could be suppressed by mutations in the contractile apparatus unc-22 (twitchin) and unc-54 (myosin) (data not shown) 9 . The hypercontracted phenotype of snf-3 egl-8 double mutants was fully synthetic: neither single mutant was hypercontracted ( Fig. 1a,b and Supplementary Fig. 1c) . The uncoordinated phenotype was also more severe than that of either single mutant ( Fig. 1c,d) . Multiple allelic combinations exhibited the same synthetic hypercontracted phenotype (data not shown), indicating that the phenotypes are not a result of background mutations.
snf-3 encodes a neurotransmitter transporter of the solute carrier 6 (SLC6) gene family. Members of this transporter family clear neurotransmitters from the synaptic cleft, including serotonin, dopamine, norepinephrine, GABA and glycine. SNF-3 is orthologous to the vertebrate betaine/GABA transporter (BGT1 or SLC6A12). Although we do not fully understand the genetic interaction between the betaine transporter and PLCβ, the synthetic phenotype provided a selection with which to identify the betaine receptor.
Hypercontraction in snf-3 egl-8 is mediated by acr-23
Mutations in SLC6 transporters often result in constitutive signaling because the neurotransmitter cannot be cleared from the synaptic cleft 18, 19 . For example, mice lacking the dopamine transporter are hyperactive 20 , whereas worms lacking the same gene have defects in their locomotor behaviors 21, 22 . These defects are consistent with the role of dopamine in the control of locomotion.
To determine whether the phenotype of snf-3, egl-8 mutants is a result of constitutive betaine signaling, we screened for suppressors of the snf-3 synthetic phenotype. Specifically, we mutagenized snf-3 egl-8 double mutants with N-ethyl-N-nitrosourea (ENU) and screened for suppressors of the hypercontracted phenotype (Fig. 1e) . We screened 37,000 haploid genomes and obtained 35 suppressors. The phenotypes of the triple mutants fell into three broad classes: those that resembled egl-8 single mutants (snf-3-specific suppressors), those that resembled snf-3 mutants (egl-8-specific suppressors) and those with new phenotypes.
The strongest snf-3-specific suppressor was the mutation ox429. We identified the suppressor mutation by genome resequencing and by transgenic rescue. ox429 is an allele of the acr-23 gene (acetylcholine receptor like-23) (Supplementary Fig. 2a ). acr-23 encodes a nematode-specific ligand-gated channel subunit and is predicted to function as a cation channel based on its sequence homology to acetylcholine receptors ( Supplementary Fig. 2c ). The only known function of ACR-23 is that it imparts sensitivity to the new class of anthelmintic drugs known as AADs. Genetic screens for AAD resistance in C. elegans identified 27 independent mutations in a single target, acr-23 (ref. 14) , and mutations in related receptor subunits in the same subfamily do not confer resistance to AAD 23 .
acr-23(ox429) fully suppressed the hypercontracted ( Fig. 1f ) and uncoordinated phenotypes ( Fig. 1g ) of the snf-3 egl-8 double mutants. For example, the double mutants were completely paralyzed in liquid (0% of wild-type rate; Fig. 1g ), whereas the snf-3 egl-8 acr-23 triple mutants thrashed actively (45% of wild-type rate; Fig. 1g ). A deletion allele, acr-23(ok2804), also suppressed the double mutants ( Fig. 1f-g) . The triple mutants still exhibited egl-8 phenotypes, including lethargy ( Fig. 1g) , constipation (data not shown) and a mild egg-laying defect (data not shown), suggesting that acr-23 mutations specifically suppress snf-3, but not egl-8, pathways.
SNF-3 is a Na + /Cl − -dependent betaine transporter
The vertebrate ortholog of SNF-3, betaine/GABA transporter 1 (BGT1 or SLC6A12), has two substrates, betaine and GABA. However, it has a higher affinity for GABA (K m = 93 µM) than for betaine (K m = 398 µM) 24, 25 . In contrast, we found that SNF-3 transported betaine, but not GABA. Betaine is a noncanonical amino acid that is present in all organisms ( Fig. 2a) . It acts as an osmolyte to maintain cell volume during stress 26 and as a methyl donor in the conversion of homocysteine to methionine. Betaine is acquired either by dietary uptake using a plasma membrane transporter or is generated as an oxidation product of choline 27 . Ultimately, betaine is metabolized to glycine. Figure 1 Two genetics screens reveal a betaine receptor. (a) snf-3 was identified as an enhancer of the phosopholipase Cβ mutation egl- 8(sa47) . Shown are images of an adult egl-8(sa47) mutant and an adult snf-3(ox354) egl-8(sa47) double mutant that were isolated in the screen. Mean lengths of 26 (egl-8) and 30 (snf-3; egl-8) adults are shown. (b) Hypercontracted phenotype. We plotted the mean body length of young adult worms. Error bars represent s.e.m. ***P < 0.001 relative to wild type and single mutants. (c) Quantification of locomotion in liquid using a thrashing assay. (d) Average locomotion speed over a 5-min period on an agar plate without food. Speed was determined using an automated worm tracking system. (e) acr-23 was isolated as a suppressor of the snf-3 egl-8 hypercontracted phenotype. Images of adult hermaphrodites of the snf-3(ox354) egl-8(sa47) double mutant (n = 30) and the snf-3(ox354) egl-8(sa47) acr-23(ox429) triple mutant (n = 29). (f,g) Quantification of the hypercontracted (f) and locomotion (g) phenotypes. Data represent the mean ± s.e.m. ***P < 0.001 compared to other mutants. For all histograms, the number of worms tested is shown inside each bar. Statistical significance was determined using one-way ANOVA followed by Tukey post hoc comparisons. # indicates data are the same as shown in b and c. To rapidly screen for the relevant substrate, we expressed SNF-3 in Xenopus oocytes and applied potential transport molecules. SLC6 transporters co-transport ions along with substrate molecules and are therefore electrogenic. We tested candidate substrates and found that only betaine induced a specific current ( Supplementary Fig. 3a) . GABA, the betaine metabolites dimethylglycine, N-methylglycine and glycine, and other related compounds are not substrates of the SNF-3 transporter.
To characterize the transport kinetics of SNF-3, we measured the accumulation of radio-labeled betaine in human retinal pigment epithelial (HRPE) cells, which do not express an endogenous betaine transporter. The expression of SNF-3 increased betaine uptake by more than 100-fold (108 ± 3 pmol per 10 6 cells per min) over control cells (0.8 ± 0.1 pmol per 10 6 cells per min). SNF-3-mediated transport was saturable with a K m of 320 ± 50 µM ( Fig. 2b) ; this value is similar to the affinity of BGT-1 for betaine (398 µM) 24 . As expected for protein-mediated transport, activity was saturable over a range of concentrations ( Fig. 2b and Supplementary Fig. 3b ) and voltages ( Supplementary Fig. 3c ). Similar to other SLC6 transporters, SNF-3 requires sodium and chloride to move substrates into cells against their chemical gradient. The absence of sodium (in N-methyl-d-glucamine (NMDG) chloride solution) or the absence of chloride (sodium gluconate solution) abolished betaine uptake ( Fig. 2c and Supplementary  Fig. 3d ), and transport was voltage dependent ( Supplementary  Fig. 3e ). The Michaelis constant of SNF-3 for sodium (K 0 5 . Na ) was 37 ± 1 mM with a Hill coefficient of 2.2 ± 0.1 ( Supplementary  Fig. 3f ), and the corresponding value for chloride (K 0 5 . Cl ) was 12 ± 1 mM with a Hill coefficient of 1.0 ± 0.1 (Supplementary Fig. 3g ). Thus, these data indicate that SNF-3 functions as a betaine transporter with a unidirectional influx of 1 betaine:2 Na + :1 Cl − per transport cycle.
In contrast with BGT1, SNF-3 did not transport GABA in our biochemical assays, and we observed this lack of GABA transport activity functionally. In the nematode, the GABA transporter is encoded by snf- 11 (ref. 28) . Overexpression of the SNF-3 transporter is unable to compensate for the absence of the GABA transporter SNF-11 even when overexpressed under the snf-11 promoter, indicating that SNF-3 cannot transport GABA in vivo 28 . The presence of a dedicated transporter suggests that betaine may have a specific role in cell signaling.
SNF-3 is required for betaine clearance
Members of the SLC6 transporter family clear neurotransmitters from synapses and the extrasynaptic space, thereby limiting their activity. To determine where SNF-3 functions, we examined snf-3 expression using a functional snf-3-GFP transgene (Supplementary Fig. 1b ). Transgenic worms displayed strong expression in the excretory canal, tail hypodermal cells, epidermis and vulval epithelia cells ( Fig. 3a) . SNF-3 was also expressed in some neurons, including the excretory canal-associated neuron (Fig. 3a) , and some sensory neurons in the head including ILs, OLs, ADE and AQR ( Supplementary Fig. 2d,e ). We were able to rescue the hypercontraction and the locomotory phenotypes of snf-3 egl-8 double mutants by expressing wild-type SNF-3 using the native snf-3 promoter or using tissue-specific promoters for the excretory canal or skin (glt-3 and pdi-2 promoters, respectively; Fig. 3b ). Notably, expressing SNF-3 in tissues that do not normally express the gene, such as the intestine, chemosensory neurons or acetylcholine motor neurons, also rescued the hypercontracted phenotype (Fig. 3b) . Rescue required expression during larval development: expression of SNF-3 in the intestine during larval development (vha-6 promoter), but not in the adult (vit-2 promoter; Fig. 3b ), rescued the hypercontracted phenotype. This stagedependent rescue is consistent with the retarded larval development of snf-3 mutants ( Supplementary Fig. 2e) . The non-cell autonomous rescue of the snf-3 egl-8 phenotypes suggests that the hypercontracted and locomotory phenotypes are caused by a lack of betaine clearance; presumably any tissue, not just the epidermis and excretory canal, can remove the excess betaine.
In contrast with snf-3, egl-8 was required in the nervous system, but not epidermis ( Fig. 3c ). Further analyses of EGL-8 revealed that the observed synthetic hypercontraction was a result of a defect in acetylcholine neurons (unc-17 promoter). Expression in sensory neurons (data not shown) or in ventral cord motor neurons (data not shown) did not rescue the double-mutant phenotypes. Thus, the functional requirements for EGL-8 and SNF-3 are in separate tissues; the transporter SNF-3 functions primarily in the epidermis to clear betaine from the extracellular space, whereas EGL-8 is required in the nervous system to modulate neuronal activity.
Exogenous betaine paralyzes snf-3 mutants
These data suggest that the phenotypes caused by snf-3 mutants are a result of excess betaine in the extracellular space. If true, then high levels of exogenous betaine should mimic snf-3 phenotypes. We grew C. elegans on different concentrations of betaine and tested their locomotion in liquid. Wild-type worms were not affected by 50 mM betaine ( Fig. 3d) . egl-8 mutants were hypersensitive to 50 mM betaine and became sluggish in liquid, but they did not become hypercontracted. snf-3 mutants were strongly hypersensitive to 50 mM betaine and were paralyzed in liquid. The toxic effect of betaine was mediated by ACR-23, as snf-3 acr-23 double mutants were resistant to exogenous betaine ( Fig. 3d) . Wild-type worms grown at a higher npg a r t I C l e S concentration of betaine (250 mM) exhibited slowed swimming in the presence of betaine ( Fig. 3e) , whereas worms overexpressing the SNF-3 transporter were resistant to 250 mM betaine ( Fig. 3e) . These data suggest that excess betaine suppresses locomotion and that the SNF-3 betaine transporter clears betaine from the extracellular space. snf-3 mutants exhibited locomotory phenotypes even if excess betaine was not applied (Fig. 1c,d ), suggesting that betaine may already be present in worms. To determine betaine levels in C. elegans, we performed proton nuclear magnetic resonance (NMR) spectroscopic analysis on the worm metabolome. Betaine was present in extracts of worms at 7.0 ± 1.0 µM per mg of dry pellet (Fig. 3f) ,
whereas the concentrations of GABA and acetylcholine were below detection (data not shown). Total betaine content did not change in snf-3 mutants; however, a redistribution to the extracellular space would not be detectable in assays of whole worms. Notably, concentrations of the metabolites choline and glycine were higher in snf-3 mutants ( Fig. 3f ). Levels of betaine in C. elegans are controlled in part by diet 29 . To confirm that our E. coli strains released betaine in the media, we measured the concentration of betaine in the media. We found that the bacterial media contained betaine at 2.3 ± 0.5 mM ml −1 , demonstrating that betaine was readily available from food. The differences between the egl-8 control and rescue of the snf-3 egl-8 double mutant by expression of snf-3(+) in the excretory canal (P = 0.0088) or in the acetylcholine motor neurons (P = 0.0031) were statistically significant. Bottom, for the locomotion phenotype, the differences between egl-8 control and rescue in the skin (P = 0.0003) and intestine (P = 0.0048) rescue were statistically significant. Expression of SNF-3 in the acetylcholine motor neurons did not rescue snf-3 egl-8 locomotory defects (P = 0.37), possibly because SNF-3 activity is electrogenic and interferes with motor neuron function. ns indicates not statistically significant. Native tissues are cells that expressed the snf-3 gene, whereas non-native tissues are cells in which snf-3 gene expression was not detected. 11× 0   16  16  17  17  25  39  40  29  18  19  19  19  18  18 
ACR-23 forms a homomeric betaine receptor
To test whether betaine acts directly on the ACR-23 receptor, we expressed ACR-23 in Xenopus oocytes and examined its response to various ligands. ACR-23 forms an ion channel that is activated by betaine, but not by acetylcholine, choline, glycine, or GABA (Fig. 4a) .
The sensitivity of ACR-23 for betaine is relatively weak; the half maximal concentration (EC 50 ) for betaine is 1.4 mM with a Hill coefficient of 1.2 ± 0.1 (Fig. 4b,c ) compared to an EC 50 of 40 µM for GABA receptors that function at the C. elegans neuromuscular junction 30 . Although we could not confirm the EC 50 by recording from larval muscles in vivo, the sensitivity of the channel to betaine is consistent with the high K m of the betaine transporter (~0.3 mM) and the concentrations of betaine found in extracellular space (~0.2 mM in mammals) 24 . ACR-23 is likely to be a nonselective monovalent cation channel. Similar to other cation channels, ACR-23 lacks a proline at the −2′ position and has a glutamate at the −1′ position of the TM2 poreforming helix 31 (Supplementary Fig. 2c ). Betaine-induced inward currents reversed at −9.4 ± 0.9 mV (Fig. 4d) , which is consistent with a nonselective cation channel. To examine cation permeability, we replaced Na + in the extracellular solution with the large impermeant cation NMDG. NMDG largely abolished betaine-evoked inward currents and shifted the reversal potential to −42.8 ± 5.6 mV, indicating that monovalent cations contribute substantially to the ACR-23 current ( Fig. 4d) . To determine whether the ACR-23 channel is permeable to K + ions, we replaced external NaCl with KCl. These conditions did not cause a shift in the reversal potential (∆E rev = 0.6 ± 0.7 mV; Fig. 4e) , indicating that the channel was also permeable to K + ions and exhibited no selectivity between Na + and K + (P Na /P K = 1.0). Two experiments revealed that ACR-23 exhibited little or no divalent cation permeability. First, we tested whether betaine-evoked currents could activate the endogenous Ca 2+ -activated chloride channels in Xenopus oocytes, which can be activated by calcium, but not barium, influx through calcium-permeable ion channels 32 . However, replacement of extracellular Ca 2+ with Ba 2+ did not alter betaine-evoked currents in oocytes (data not shown). Second, increasing the concentration of Ba 2+ tenfold failed to elicit a substantial shift in betaine-evoked reversal potential (∆E rev = 1.1 ± 1.1 mV; Fig. 4f ). Thus, ACR-23 forms a homomeric betaine-gated ion channel that is nonselective for monovalent cations.
ACR-23 was first isolated as the target of the anthelmintic drugs known as AADs, commercially available as Zolvix, containing the AAD monepantel 14 . However, the pharmacological effects of this drug on the ACR-23 receptor have never been tested because the endogenous ligand of ACR-23 was not known 15 . To determine the effects of monepantel on ACR-23, we applied 300 pM monepantel (diluted Zolvix) to ACR-23-expressing oocytes. Monepantel did not elicit any current by itself, but instead potentiated betaine-induced currents (Fig. 4g) . It was recently observed that 1,000-fold higher concentrations of monepantel (300 nM) can act as an agonist of ACR-23 (ref. 33) . At 300 pM, monepantel did not activate the ion npg a r t I C l e S Gain-of-function ACR-23 resembles snf-3 egl-8 mutant Together, these data suggest that an increase in betaine levels in the snf-3 egl-8 double mutants inappropriately activates ACR-23 and leads to hypercontraction. To demonstrate that constitutive activation of ACR-23 could generate the hypercontracted phenotype, we generated an ACR-23 receptor with a higher ligand sensitivity. The second transmembrane domain forms the pore in ligand-gated ion channels and the residues are numbered 0′ to 19′ by convention 35 . Mutations at the 13′ position of the pore are known to increase the ligand sensitivity and conductance of cys-loop ion channels, probably by affecting transitions to the open state 31 . We engineered a variant at the 13′ position, ACR-23(I301N), based on known gain-of-function mutations in a related receptor 36 (Supplementary Fig. 2c ). Similar to other receptors 31 , ACR-23(I301N) was more sensitive to betaine and the channel desensitized less than the wild-type receptor (Fig. 4c) .
The EC 50 for the receptor decreased eightfold, from 1,400 µM to 166 µM (Fig. 4c) . This hypersensitive variant of ACR-23 in transgenic worms recapitulated the snf-3 egl-8 double mutant phenotype. Most ACR-23(I301N) transgenic worms died during larval development. Those that escaped lethality and reached adulthood were severely hypercontracted ( Supplementary Fig. 2d and Fig. 5e ) and uncoordinated (Fig. 5f) , closely resembling the phenotype of snf-3 egl-8 mutants. We also evaluated the tissue-specific effects of the gain-of-function ACR-23(I301N) mutation. Expressing ACR-23(I301N) in body channel and had no effect on the size of the initial betaine-induced current, but it did block the desensitization of the ACR-23 receptor (Fig. 4g) . In addition, 60 s after the initial application of betaine, the current amplitude was 5.3 ± 0.9-fold larger in the presence of monepantel than in its absence. Thus, monepantel functions as a positive allosteric modulator of betaine gating. Allosteric modulators, such as benzodiazepines and barbiturates that positively enhance GABA transmission, alter the response of the receptor to its natural ligand without competing for the binding site.
ACR-23 acts in the nervous system to regulate locomotion
To determine where ACR-23 functions during locomotion, we characterized the expression pattern of the acr-23 gene using transcriptional mCherry reporter constructs ( Fig. 5a and Supplementary Fig. 2b) . acr-23 was expressed strongly in the six mechanosensory neurons, multiple interneurons and body muscles. ACR-23 expression in muscle was high in larvae and weak in adults. The expression of acr-23 in the larval body muscles was consistent with the hypercontraction phenotype observed in snf-3 egl-8 double mutants.
The lack of expression in motor neurons was surprising to us because mutants lacking acr-23 (Supplementary Fig. 1c ) exhibited mild swimming defects (Fig. 1g) , were lethargic when crawling on an agar plate (Fig. 5b,c) and their movement was interrupted by frequent pauses. snf-3 mutants and snf-3 acr-23 double mutants were equally sluggish ( Figs. 1g and 5b,c) , suggesting that the effect of betaine on locomotion is mediated by different receptors.
To determine where ACR-23 functions during locomotion, we rescued the mutant using tissue-specific promoters. Expression in the nervous system rescued the locomotory phenotypes of acr-23 mutants (Fig. 5d) . Expression in the mechanosensory neurons also partially restored motor activity (Fig. 5d) , consistent with the known role of these cells in controlling basal levels of locomotion 34 . Thus, as with egl-8, acr-23 is required in the nervous system. These data suggest that phospholipase Cβ limits ACR-23 function in the nervous system, either directly or indirectly. npg a r t I C l e S muscles alone generated hypercontracted worms that only exhibited modest locomotion defects (Fig. 5e,f and Supplementary Fig. 2e) . Conversely, expression of ACR-23(I301N) in the mechanosensory neurons resulted in morphologically wild-type worms that exhibited uncoordinated thrashing in liquid (Fig. 5e,f and Supplementary  Fig. 2d ). These data are consistent with ACR-23 acting in part via the nematode somatosensory circuit to modulate locomotion.
DISCUSSION
Using two forward genetic screens, we uncovered the molecular pathway that leads to betaine toxicity in nematodes. ACR-23 is a betainegated cation channel expressed in body muscle and neurons. The betaine transporter SNF-3 removed betaine from the extracellular space (Supplementary Fig. 4) . In the absence of snf-3, betaine was able to accumulate in the extracellular space, and snf-3 mutants exhibited subtle locomotory phenotypes. These phenotypes were exacerbated by mutations in phospholipase Cβ. In the snf-3 egl-8 double mutant, constitutive activation of ACR-23 led to hypercontraction, paralysis and sometimes death as a result of a combination of effects on the nervous system and muscle. Why phospholipase Cβ mutations are synthetic with mutations in the transporter is not clear; however, one possibility is that phospholipase Cβ is required to downregulate ACR-23 itself or the activity of the neurons in which it functions. Thus, the elimination of the receptor by mutation restores muscle function and locomotion, reversing the effect of the snf-3 and egl-8 mutations.
In addition to its natural ligand betaine, ACR-23 is also the target of a class of anthelmintic drugs known as AADs, which contain the active compound monepantel 14 . Monepantel induces muscle hypercontraction, spasmodic pharyngeal contraction, paralysis and death in C. elegans 14 . These characteristics are shared with other anthelmintic drugs that activate ligand-gated ion channels in the nematode. Unlike these receptor agonists, monepantel acted as an allosteric modulator of ACR-23, potentiating betaine signaling during development, resulting in nematode death. A drawback of monepantel is that some of the genera lacking the acr-23 gene include parasitic nematodes 23 , such as Strongyloides and Ascaris, which represent a major public health concern in developing countries. Unlike acr-23, SNF-3 has an ortholog in most parasitic nematodes species with a sequenced genome. Thus, the betaine-SNF-3 pathway offers a unique set of targets that can be used to improve AAD efficiency or to develop new anthelmintic drugs.
What then is the normal role of betaine in the nematode? Betaine signaling was required in C. elegans for basal levels of locomotion: acr-23 mutants were sluggish when crawling on agar. The effect on locomotion was mediated in part via ACR-23 receptors expressed in the mechanosensory neurons. The mechanosensory neurons innervate the locomotory command neurons to stimulate touchinduced movement as well as spontaneous levels of locomotion 37, 38 . The mechanosensory neuron dendritic processes run adjacent to the epidermis and, in some cases, are completely embedded in the epidermal cells expressing the betaine clearance transporter SNF-3. We cannot exclude the possibility that betaine is acting as a conventional neurotransmitter, that is, that it is released onto neurons and muscles at synapses. However, it is also possible that betaine is released by the epidermis rather than by neurons. In this model, the skin may both release betaine onto the mechanosensory processes and clear it from the space between the skin and dendrite, acting as both source and sink for this neurotransmitter.
Betaine has been shown to have anticonvulsant properties in vertebrate brain [5] [6] [7] , but its mechanisms of action have not been elucidated. Although acr-23 is not conserved in the vertebrate, snf-3 and phospholipase Cβ are conserved and expressed in the vertebrate nervous system. The mammalian nervous system contains many uncharacterized ligand-gated ion channels and G proteincoupled receptors. Some of these could potentially mediate betaine anticonvulsive properties.
METHODS
Methods and any associated references are available in the online version of the paper.
Note: Any Supplementary Information and Source Data files are available in the online version of the paper.
ONLINE METHODS enhancer screen. We mutagenized EG4094 egl-8(sa47) V; oxEx771[B0348 egl-8(+); rol-6(sd); Pmyo-2øGFP] with 20 nM ENU. B0348 is a cosmid that rescues egl-8. We singled individual F 1 and F 2 offspring carrying the plcβ rescuing extrachromosomal array oxEx771[B0348 (egl-8 + ; rol-6(sd); Pmyo-2øGFP]. We screened F 3 offspring for the presence of an enhancer by looking for new phenotypes in non-GFP-expressing siblings (plcβ mutant background) that were not observed in GFP-expressing siblings (plcβ rescued). We screened 1,669 haploid genomes and isolated snf-3(ox354) from this screen.
We mapped snf-3(ox354) to the left arm of chromosome II using single nucleotide polymorphism mapping 39 . The region was further narrowed by rescuing snf-3 using standard microinjection transgenic techniques 40 . snf-3(ox354) was rescued by injecting snf-3(ox354), egl-8(sa47) worms with a pool of cosmids F45D11, M01D1 and C07D2 along with 2 ng µl −1 Pmyo-2øGFP co-injection marker. Each cosmid was injected at 20 ng µl −1 . Cosmid C07D2 alone was sufficient to rescue the snf-3(ox354) enhancer defects. We were able to rescue snf-3(ox354) by injecting four overlapping PCR fragments from wild-type genomic DNA of the T13B5.1 gene. To identify the molecular lesion in snf-3(ox354), we sequenced snf-3 PCR fragments generated from snf-3(ox354) egl-8(sa47) double mutant worms.
Suppressor screen. We mutagenized EG7081 snf-3(ox354) egl-8(sa47) with 20 nM ENU. We screened the F 2 progeny for non-hypercontracted and non-uncoordinated worms. We screened a total of 37,000 haploid genomes. We isolated acr-23(ox429) from this screen.
To identify the mutation ox429, we resequenced the genome of EG6501 snf-3(ox354) egl-8(sa47) acr-23(ox429) using an Illumina Genome Analyzer II (GAII). The molecular lesion in acr-23(ox429) was confirmed using traditional Sanger sequencing. To rescue acr-23(ox429), we injected snf-3 egl-8 acr-23 triple mutants (EG6501) with either four overlapping PCR fragments with a 1-kb overlap (25 ng µl −1 each) of acr-23 genomic DNA or a full-length acr-23 gene with 2 ng µl −1 Pmyo-2ømCherry co-injection marker. From injections of these two constructs, we obtained over ten transgenic lines with the restoration of the hypercontracted phenotype observed in simple snf-3 egl-8 double mutants. Most of these transgenic strains were very sick and hard to maintain. We further confirmed that ox429 was an allele of acr-23 by crossing a null allele of acr-23(ok2804) into snf-3 egl-8 double mutants to generate snf-3 egl-8 acr-23(ok2804) (EG6544) worms. molecular biology. To create a full-length genomic snf-3 DNA plasmid, we excised a 15-kb genomic fragment of snf-3 from C07D2 using StuI and restriction digest and ligated it into pLITMUS38 (pADA49). To generate a fluorescently tagged SNF-3, we cut the GFP with MluI from the pPD114.24 vector (A. Fire, Stanford University), and ligated it into an MluI site in the largest intron in frame with the gene to generate pADA65. The GFP tag is located in the extracellular loop between transmembrane domain 9 and 10. 30 ng µl −1 of pADA65 was injected in snf-3(ox354) egl-8(sa47) along with 2 ng µl −1 Pmyo-3ømCherry and Punc-122øGFP co-injection marker. Multiple transgenic lines were obtained and they fully rescued snf-3(ox354) enhancer defects (strain EG4769 carries oxEx1067). We also tagged SNF-3 at the N terminus by ligating Psnf-3 and the snf-3 coding region into the GFP vector pPD117.01 (A. Fire) to generate pADA73. 10 ng µl −1 of pADA73 was injected into lin-15(n765ts) along with 2 ng µl −1 Pmyo-3ømCherry co-injection marker and lin-15(+)(pL15EK). We generated EG6888 from these injections. To visualize neurons expressing SNF-3øGFP, we subjected EG6888 to RNAi feeding plates against GFP (pPD128.110). For tissue-specific rescue, we used the MultiSite Gateway Pro 3-fragment recombination technology (Invitrogen, catalog no.12537-023). All constructs containing a promoter were inserted into the pDONR P4-P1 vector (slot 1). These promoters contained the initiating start codon (ATG). snf-3 cDNA, lacking the ATG, was inserted into the pDONR 221 vector (slot 2). The C-terminal tag fluorescent protein (GFP or mCherry) followed by the 3′UTRs of unc-54 or let-858 gene were inserted into pDONR P2R-P3 vector (slot 3). The final recombination product was inserted into pDEST R4-R3 vector.
To create rescuing constructs for egl-8, we used MultiSite Gateway Technology. egl-8 cDNA without an ATG was inserted into the pDONR 221 vector (slot 2).
To create a full-length genomic acr-23 construct, we divided the genomic region into three fragments that were inserted into different Multisite Gateway pDONR vectors. A 2.9-kb promoter and the full genomic region except for the last two exons of the gene were inserted into the pDONR P4-P1 vector. The 4-kb intron and exon 8 were inserted into the pDONR 221 vector, and the last exon and the 3′ UTR (252 bases) were inserted into pDONR P2R-P3 vector. These three fragments were recombined with pDEST R4-R3 vector to create pADA246. To create pASP268, we inserted mCherry in operon between the last exon of the gene and the 3′ UTR in the pDONR P2R-P3 vector using Gibson Assembly Cloning technology (New England Biolab). The intergenic region of the gdp-2 gdp-3 was used to express mCherry from an operon. All the constructs used for tissue specific rescues were created using the MultiSite Gateway Technology. An acr-23 cDNA containing an ATG was inserted into the pDONR 221 vector. In this case, the corresponding promoters (Pmyo-3, Prab-3 and Pmec-7) in slot 1 lack ATG. confocal microscopy. We acquired images of fluorescently tagged fusion proteins in living C. elegans with a 63× 1.4 NA oil objective on a Pascal LSM5 confocal microscope (Carl Zeiss).
Body length assay.
We selected L4 worms the day before the assay for each genotype studied. On the day of the experiment, we anesthetized adult worms with 15 mM sodium azide in M9 solution on freshly made 2% agarose pads. We used a plan-Neofluar 10× 0.3 NA objective on a Pascal LSM5 confocal microscope. The size of the worm was determined using a build-in function on the LSM5 image browser. growth assay. We plated 10 L4 larvae on NGM plates 12 h before we started the experiment. We transferred the adults every 6.5 h (at 22.5 °C) or overnight (12 h) at 15 °C. After the animals were transferred, we counted the number of eggs laid. We monitored hatching rate and development rate to adulthood. Adulthood was determined by the presence of a vulva. The percentage of worms was normalized to each plate.
Betaine assay. We top-spreaded NGM plates with betaine to obtain a final concentration of 50 and 250 mM. These plates were allowed to dry at 22.5 °C for 24 h and then seeded with the E. coli strain OP50. On the day of the experiment, we added three L4 worms to each plate. The plates were coded so the experimenter was blind to betaine concentrations and genotype of the strains. The first and second generations progeny were then tested in a thrashing assay. For the snf-3 overexpression line (EG8093), the array oxEx1208 was crossed out from strain EG5051 and crossed twice against N2.
thrashing assay for locomotion. Single young adult worms were placed in a microtiter well in a 96-well plate without agar, containing 150 µl of water. Assays in M9 yielded similar results (data not shown). The worm was allowed to acclimate for 2 min and we counted thrashes for 60 s. One thrash reflects the bending of the body from the midbody toward one side of the animal and back again. The value obtained is doubled to reflect the true number of bends.
crawling assay for locomotion. We transferred well-fed young adult worms to a food-free NGM plate (100 mm). Worms were allowed to acclimate for 5 min and we counted the number of body bends generated by each worm every 20 s. Each worm was tested four times.
crawling speed assay. The speed of the worm was determined using an automated worm tracking and analysis system. A single young adult worm was transferred to a food-free NGM plate (100 mm) placed on a motorized microscope stage (OptiScan ES111, Prior Scientific). After a 1-min acclimation period, the worm was imaged at 5 frames per s for 5 min using a VGA FireWire camera (XCD-V60, Sony) mounted on a Leica MS5 stereomicroscope. A custom MATLAB program 41 (MathWorks) was used to control the camera and the motorized stage and to determine the mean locomotion speed. The speed was calculated based on the distance traveled by the worm over 5 min.
Statistical analysis. Statistical analyses were performed using Kaleidagraph 3.6 and GraphPad Prism 6. All grouped data are reported as means ± s.e.m.
npg Statistical significance between genotypes was determined using one-way ANOVA followed by Tukey post hoc comparisons. We used two-tailed unpaired Student's t test with Welch's correction to determine the difference between wild-type and the gain-of-function (Fig. 4c) . Logarithmic normal distribution was assumed for betaine EC 50 values, so we use the pEC 50 values for statistical analysis. P < 0.05 was considered statistically significant. No statistical methods were used to predetermine sample sizes, but our sample sizes are similar to those reported in previous publications in the field (thrash assay 42 , speed 41 , body bends 21 and body length 43 ). Data distributions were assumed to be normal, but this was not formally tested. Data collection and analysis were not always performed blind, but we specifically state which experiments were performed blind in the Online Methods. All of the data were collected and processed side by side in a randomized manner.
SnF-3 transport assay in HRPe cells. HRPE cells were transfected using a vaccinia virus expressing snf-3 cDNA as described previously 44, 45 . HRPE cells grown in 24-well plates were infected with a recombinant vaccinia virus (VTF7-3). This virus carries the gene for T7 RNA polymerase. The virus was allowed to adsorb onto the cells for 30 min at 37 °C with gentle shaking of the plate. Cells were then transfected with the plasmid DNA (empty vector pSPORT1 or snf-3 cDNA construct) using the lipofection procedure (Invitrogen). The cells were incubated at 37 °C for 12 h and then assayed for transport activity. The uptake of [ 14 C]betaine (2.5 µM) was determined at 37 °C. In most experiments, the media consisted of 25 mM Hepes/Tris (pH 7.5), 140 mM NaCl, 5.4 mM KCl, 1.8 mM CaCl 2 , 0.8 mM MgSO 4 , and 5 mM glucose. In experiments in which the cation and anion dependence of the transport process was investigated, NaCl was replaced isoosmotically by sodium gluconate or NMDG chloride. Uptake measurements were routinely made in parallel in control cells transfected with vector alone and in cells transfected with the vector-cDNA construct. The uptake activity in cDNAtransfected cells was adjusted for the endogenous activity measured in control cells to calculate the cDNA-specific activity. Experiments were performed in triplicate, and each experiment was repeated at least three times. Results are presented as means ± s.e.m. The kinetic parameters, Michaelis-Menten constant (K m ) and maximal velocity (V max ) were calculated by fitting the data to a Michaelis-Menten equation describing a single saturable transport system. Analysis was done by nonlinear regression, and the resultant values for the kinetic parameters were confirmed by linear regression.
SnF-3 analysis. The procedures for cRNA in vitro transcription, Xenopus laevis oocyte isolation, microinjection, superfusion, voltage clamping and data analysis have been described previously 45, 46 . Briefly, the plasmid SNF-3øpSPORT1 was linearized with NotI and transcribed in vitro to cRNA using the mMESSAGE mMACHINE RNA transcription kit (Ambion). The expression of SNF-3 was initially detected by comparing the uptake of (2.5 µM) [ 14 C]-betaine (55 mCi mmol −1 , American Radiolabeled Chemicals) in water-injected oocytes versus SNF-3-injected oocytes. The electrophysiological characteristics of the heterologously expressed SNF-3 were then studied using a GeneClamp 500 (Axon Instruments). Kinetic parameters for the saturable transport of SNF-3 were calculated using the Michaelis-Menten equation. Data were analyzed by nonlinear regression and confirmed by linear regression.
AcR-23 analysis. ACR-23 analysis was performed as described previously 47 . To generate plasmid constructs for Xenopus oocyte expression, we subcloned full-length error-free ACR-23 cDNAs and ACR-23 gain-of-function (ACR-23(I301N)) into the pSGEM expression vector using the SLIC cloning technique 48 to produce pADA206 and pADA278. RNAs were prepared using the T7 mMessage mMachine kit (Ambion). Capped ACR-23 (0.1-5 ng total) or ACR-23(I301N) (0.5-2.5 ng total) RNAs were injected into Xenopus oocytes. 1-4 d post-injection, two-electrode voltage-clamp recordings were performed. Voltage was clamped at −60 mV. The standard bath solution was Ringer's: 115 mM NaCl, 2.5 mM KCl, 1.8 mM CaCl 2 , 10 mM Hepes, pH 7.2 (NaOH). Each oocyte was subjected to 20-s applications of agonist with a 2-min wash between test applications. Expression of ACR-23(I301N) was very toxic to Xenopus oocytes. We only used healthy oocytes with low channel expression for further analysis of this receptor. Eight oocytes were used to characterize the betaine concentration-response relationship of ACR-23(I301N), but individual oocytes were not tested through the full range of active concentrations. Three oocytes were tested at 0.001-0.003 mM, five were tested at 0.01-0.3 mM, and all were tested at 1-10 mM. Curves were fit to data from the five oocytes with data in the linear response range to perform statistical analysis of EC 50 values.
Ion selectivity. For voltage-ramp experiments, CaCl 2 was replaced by BaCl 2 in the extracellular solutions to eliminate possible contributions from the endogenous Ca 2+ -activated chloride channel. To assay sodium permeability, we substituted 115 mM NMDG chloride for NaCl. Thus, Na-free solution contains 115 mM NMDG, 2.5 mM KCl, 1.8 mM BaCl 2 , and 10 mM Hepes, pH 7.2 (HCl). To compare sodium and potassium permeability, NaCl was replaced with equimolar KCl: 115 mM KCl, 2.5 mM NaCl, 1.8 mM BaCl 2 , 10 mM Hepes, pH 7.2 (KOH). To assay barium permeability, BaCl 2 was increased tenfold: 115 mM NaCl, 18 mM BaCl 2 , 2.5 mM KCl, 10 mM HEPES, pH 7.2 (NaOH). The osmolarity of each solution was adjusted to 300 mOsm with sucrose. Reversal potentials were measured using 2-s voltage ramps (−100 mV to +60 mV) during sustained betaine application. Reversal potential shifts were similar at various time points after initiating betaine perfusion. Ramps at 20 s were analyzed for the potassium substitution experiment because of changing rectification characteristics at later time points, whereas ramps at 60 s were used for all other analyses. An agar bridge was used to minimize changes in junction potentials when switching solutions. Small residual voltage offsets due to differing ion composition in perfusion buffers were measured relative to standard solution before each voltage ramp recording, and were subtracted from the amplifier command voltages during data analysis. Data analysis was performed using Igor software (WaveMetrix). All chemicals were purchased from Sigma Chemical. monepantel. Commercially available Zolvix (25 mg ml −1 monepantel, Novartis) was diluted in DMSO to make a 10 mM stock solution of monepantel. The stock solution was diluted in water to make a 10 µM working stock in 0.1% DMSO. Final concentrations were achieved by diluting in Ringer's to make the experimental perfusion solutions. 1 mM betaine was applied for 60 s either alone or in the presence of 0.3 nM monepantel following a 40-s preapplication of monepantel alone. All perfusion buffers were supplemented with 0.1% DMSO. Peak current magnitudes in three 10-s time windows were compared in the presence and absence of monepantel immediately after applying monepantel alone, immediately after initiating betaine application and 50 s after sustained betaine application. culture of nematodes. Strain genotypes were blinded to the experimenter. Early embryos were isolated by alkaline hypochlorite treatment and plated after synchronization on NGM plates seeded with HB101 bacteria as a food source at 20 °C. For each biological replicate, ~8,000 worms were harvested, washed twice with M9, twice with water and stored at −80 °C until extraction. Eight samples were grown for each strain. extraction procedure for metabolites. Metabolites from whole nematodes were extracted using a methanol-chloroform procedure. 600 µl of a methanol-chloroform mix (2:1, vol/vol) was added to the frozen nematodes. Samples were homogenized using a Polytron and sonicated for 15 min. 200 µl each of chloroform and water were added, the samples centrifuged and the aqueous layer separated from the lipid one. The procedure was repeated twice. The aqueous layer was dried overnight in an evacuated centrifuge.
Analysis of aqueous extracts. The dried extracts were rehydrated in 600 µl of D 2 O containing 0.05 mM sodium-3-(tri-methylsilyl)-2,2,3,3tetradeuteriopropionate (TSP; Cambridge Isotope Laboratories) as an internal standard. The samples were analyzed using an AVANCE II+ NMR spectrometer operating at 500.13 MHz for the 1 H frequency (Bruker) using a 5-mm TXI probe. Spectra were collected using a solvent suppression pulse sequence based on a one-dimensional NOESY pulse sequence to saturate the residual 1 H water signal (relaxation delay = 2 s, t 1 increment = 3 µs, mixing time = 150 ms, solvent presaturation applied during the relaxation time and the mixing time). 196 transients were collected into 16 K data points over a spectral width of 12 ppm at 27 °C for the adult samples. 
